TBC1D22B

Across TCGA pan-cancer cohorts, TBC1D22B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TBC1D22B data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TBC1D22B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBC1D22B expression acts as an unfavorable survival marker.

LUSC, LUAD, and SARC are the cancer types where TBC1D22B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.108	0.736	<.001	36	view →
LUAD	OS	Median	All	0.068	0.788	<.001	30	view →
SARC	DFS	Median	All	0.197	0.614	.007	9	view →
THCA	OS	Median	All	0.323	0.955	<.001	8	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TBC1D22B–LUSC (OS)

Open the LUSC breakdown →